$インベンティバー(IVA.US)$Inventiva Receives Recommendation From The 4th Scheduled Data Monitoring Committee Meeting Of The NATiV3 Phase III Clinical Trial With Lanifibranor In Patients With MASH/NASH Benzinga· The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data. The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in t...
$インベンティバー(IVA.US)$SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-New Enterprise Associates 17, L.P.(10.7%),NEA Partners 17, L.P.(10.7%), etc. SEC announcement· May 3 21:27
$インベンティバー(IVA.US)$Inventiva (NASDAQ:IVA) reported a Phase 2 study of its drug candidate lanifibranor met its primary efficacy endpoint in the treatment of patients with MASH/NASH and type 2 diabetes.
$インベンティバー(IVA.US)$Inventiva Resumes Screening In NATiV3, Phase III, Clinical Trial Evaluating Lanifibranor In NASH Benzinga· 2 mins ago Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF. Screening of patients is resuming in sites operating under central IRB in the US. Other sites and countries are expected to resume screening and randomization activities progr...
インベンティバーに関するコメント
Benzinga·
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.
The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in t...
SEC announcement· May 3 21:27
Benzinga· 2 mins ago
Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF.
Screening of patients is resuming in sites operating under central IRB in the US.
Other sites and countries are expected to resume screening and randomization activities progr...
$リープ セラピューティクス(LPTX.US)$ Phase 2
$ベラ セラピューティクス(VERA.US)$ Phase 2b
$4D モレキュラー セラピューティクス(FDMT.US)$ Phase 2
$アドベラム バイオテクノロジーズ(ADVM.US)$ Phase 2
$デナリ セラピューティクス(DNLI.US)$ Phase 2
$アケロ セラピューティクス(AKRO.US)$ Phase 2b
$スプルース バイオサイエンシズ(SPRB.US)$ Phase 2
$ゼンコア(XNCR.US)$ Phase 2
$アルナイラム ファーマシューティカルズ(ALNY.US)$ Phase 2
$ハーモニー バイオサイエンシズ ホールディングス(HRMY.US)$ Phase 2
$アネクソン(ANNX.US)$ Phase 2a
$ロイバント サイエンシズ(ROIV.US)$...
$コーバー(CWBR.US)$ 0.64
$Onfolio Holdings Inc(ONFO.US)$ 0.48
$セネステック(SNES.US)$ 1.1
close watch SOUN
$アドバンスト マイクロ デバイシズ(AMD.US)$ $ビット デジタル(BTBT.US)$ $ビットディアー テクノロジーズ グループ A(BTDR.US)$ $チューイ A(CHWY.US)$ $ドアダッシュ A(DASH.US)$ $インベンティバー(IVA.US)$ $NeoVolta(NEOV.US)$ $Eneti(NETI.US)$ $オーケストラ バイオーム ホールディングス(OBIO.US)$ $パンベラ・セラピューティクス(PBLA.US)$ $Lordstown Motors(RIDE.US)$ $Sientra(SIEN.US)$ $サウンドハウンド・エーアイ(SOUN.US)$ $Top KingWin(TCJH.US)$ $トヨタ自動車(TM.US)$
まだコメントはありません